

## PROVINCIAL FUNDING SUMMARY

### Pemetrexed (Alimta) for Non-Squamous Non-Small Cell Lung Cancer

pERC Recommendation: Recommends with condition on the cost-effectiveness being improved to an acceptable level

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: December 4, 2013

This information is current as of May 10, 2017.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
BC	Funded	May 1, 2014	Advanced non-small cell lung cancer, non-squamous cell histology; No disease progression after 4-6 cycles of first-line platinum-based doublet with or without pemetrexed; Maintenance pemetrexed is to be started 21 to 42 days after the final cycle of the first-line platinum-based doublet; ECOG performance status 0-1 at start of maintenance; BC Cancer Agency Compassionate Access Program (CAP) approval must be obtained.
AB	Funded	May 1, 2014	First line with platinum followed by maintenance pemetrexed for the treatment of advanced non-small cell lung cancer with non-squamous histology.
SK	Funded	Mar 3, 2014	Maintenance single agent treatment following 4-6 cycles of platinum doublet induction treatment, which may include pemetrexed, for patients who achieved stable disease or better and who have an ECOG performance status of 0 or 1; treatment may be continued until disease progression

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
MB	Funded	Jun 1, 2014	<p><b>Non-small cell lung cancer, 1st line therapy:</b>                      Pemetrexed in combination with cisplatin or carboplatin, for the first line treatment of patients with:</p> <ul style="list-style-type: none"> <li>- locally advanced (stage IIIB) or metastatic (stage IV) advanced non-small cell lung cancer of non-squamous cell (e.g. adenocarcinoma) histology AND</li> <li>- An Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less AND</li> <li>- Adequate bone marrow function (ANC greater than or equal to <math>1.5 \times 10^9/L</math>, platelets greater than <math>100 \times 10^9/L</math>), renal function and liver function</li> </ul> <p><b>Non-Small Cell Lung Cancer, Advanced:</b>                      Maintenance therapy following 1st line therapy: Pemetrexed for the maintenance treatment of patients with:</p> <ul style="list-style-type: none"> <li>- Advanced non-small cell lung cancer of non-squamous cell (e.g. adenocarcinoma) histology AND</li> <li>- Radiographically confirmed stable disease/disease response following completion of 1st line chemotherapy with a platinum-based doublet AND</li> <li>- An Eastern Cooperative Oncology Group (ECOG) performance status of 1 or less AND</li> <li>- Adequate bone marrow function (ANC greater than or equal to <math>1.5 \times 10^9/L</math>, platelets greater than <math>100 \times 10^9/L</math>, renal function, liver function.</li> </ul>

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
ON	Funded	Apr 1, 2014	<ul style="list-style-type: none"> <li>• As combination therapy with platinum for 4-6 cycles, for first line (or induction) treatment of locally advanced/metastatic non-squamous NSCLC. Patients who received either EGFR or ALK targeted therapy as their initial treatment may be considered for this treatment as a next line chemotherapy option.</li> <li>• As monotherapy for the maintenance treatment of locally advanced/ metastatic non-squamous NSCLC following 4-6 cycles of platinum doublet induction treatment, which may include pemetrexed, for patients who achieved stable disease or better and who have an ECOG performance status of 0 or 1; treatment may be continued until disease progression.</li> <li>• As monotherapy for the second-line (or subsequent) line treatment of locally advanced/ metastatic non-squamous non-small cell lung cancer (NSCLC) in patients who have disease progression following any non-pemetrexed treatment option; treatment may be continued until disease progression.</li> <li>• As monotherapy, for the third-line treatment of locally advanced/metastatic non-squamous NSCLC in ALK-positive patients who have failed prior 1st line non-pemetrexed chemotherapy and 2nd line crizotinib therapy and have not received pemetrexed in an earlier line of therapy. Dosing schedule: 500mg/m<sup>2</sup> on day 1, repeat 21 days until disease progression Exclusion criteria: <ul style="list-style-type: none"> <li>• Patients whose disease has progressed following pemetrexed (maintenance and/or prior lines of therapy) are not eligible for pemetrexed funding in the 2nd or subsequent line setting.</li> </ul> </li> </ul>
NS	Funded	Apr 1, 2014	In those patients who achieved stable disease or better post 4 cycles of first line pemetrexed/platinum based induction therapy and have ECOG PS of 0-1 an option to continue maintenance pemetrexed as a single agent is available (continued maintenance therapy).

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
NB	Funded	Sep 1, 2014	As first line (or induction) treatment, in combination with platinum for 4-6 cycles, in patients with locally advanced or metastatic NSCLC with non-squamous histology, who have an ECOG performance status of 0-2. , As a single agent maintenance treatment in patients with locally advanced or metastatic NSCLC with non-squamous histology, who achieved stable disease or better immediately following 4-6 cycles of pemetrexed plus platinum induction therapy and have an ECOG performance status of 0-1 (after induction therapy). As a single agent for the treatment of locally advanced or metastatic NSCLC of non-squamous histology in patients previously treated with non-pemetrexed chemotherapy (i.e. / second line therapy).
NL	Funded	Apr 1, 2014	
PEI	Funded	Nov 23, 2015	Non-Small Cell Lung Cancer (NSCLC) - Advanced, Non-Squamous Histology - First line (or Induction) chemotherapy treatment option in combination with platinum for 4-6 cycles; patients who received either EGFR or ALK targeted therapy as their initial treatment for advanced disease may be considered for this treatment as a next line chemotherapy option. - Maintenance single agent treatment following 4-6 cycles of platinum doublet induction treatment, which may include Pemetrexed, for patients who achieved stable disease or better and who have an ECOG performance status of 0 or 1; treatment may be continued until disease progression. - Second (or subsequent) line single agent treatment for patients who have disease progression following any non-Pemetrexed treatment option; treatment may be continued until disease progression. Malignant Mesothelioma - First line therapy in combination with Cisplatin.